Peter Paschka

Summary

Affiliation: Frankfurt am Main
Country: Germany

Publications

  1. doi request reprint Core binding factor acute myeloid leukemia
    Peter Paschka
    Medizinische Klinik II, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    Semin Oncol 35:410-7. 2008
  2. ncbi request reprint Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia
    Martin C Muller
    III Medizinische Universitätsklinik Mannheim der Universität Heidelberg, Mannheim, Deutschland
    Acta Haematol 112:30-3. 2004
  3. ncbi request reprint Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance
    Peter Paschka
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Acta Haematol 112:85-92. 2004
  4. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006

Collaborators

  • G Marcucci
  • Martin C Muller
  • Tanja Hördt
  • Paul La Rosée
  • Andreas Hochhaus
  • Rudiger Hehlmann
  • Kirsten Merx

Detail Information

Publications4

  1. doi request reprint Core binding factor acute myeloid leukemia
    Peter Paschka
    Medizinische Klinik II, Klinikum der JW Goethe Universität, Frankfurt am Main, Germany
    Semin Oncol 35:410-7. 2008
    ..This review summarizes the most recent laboratory and clinical discoveries relevant to this subset of AML and how they are being applied for in an effort to improve the cure rate in patients with the disease...
  2. ncbi request reprint Standardization of preanalytical factors for minimal residual disease analysis in chronic myelogenous leukemia
    Martin C Muller
    III Medizinische Universitätsklinik Mannheim der Universität Heidelberg, Mannheim, Deutschland
    Acta Haematol 112:30-3. 2004
    ..The definition of 'undetectable BCR-ABL' in an individual patient should take these preanalytical parameters into consideration...
  3. ncbi request reprint Molecular surveillance of chronic myeloid leukemia patients in the imatinib era - evaluation of response and resistance
    Peter Paschka
    III Medizinische Klinik, Fakultät für Klinische Medizin Mannheim der Universität Heidelberg, Mannheim, Germany
    Acta Haematol 112:85-92. 2004
    ..The definition of molecular surrogate endpoints beyond CCR for studies which are currently planned demands standardization of the nomenclature and of technologies to measure these targets...
  4. ncbi request reprint Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study
    Peter Paschka
    Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
    J Clin Oncol 24:3904-11. 2006
    ..To analyze the prognostic impact of mutated KIT (mutKIT) in core-binding factor acute myeloid leukemia (AML) with inv(16)(p13q22) and t(8;21)(q22;q22)...